GlassScriptPhysician profile
Caitlin N Lander
NPI 1285246132
$1,426.01
in general payments reported to CMS, 2019-2025
26 companies · $277 in 2025
The $277 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $406 · 2023: $108 · 2024: $635 · 2025: $277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,020.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $190.81 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.42 | 2022-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $152.41 | 2022-2025 | Mounjaro, Zepbound |
| Amgen INC. | $143.23 | 2022-2025 | Evenity, Prolia |
| Qol Medical, LLC | $116.72 | 2023-2024 | Sucraid, Sucraid |
| Novo Nordisk INC | $75.95 | 2022-2024 | Wegovy, Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $72.72 | 2024 | |
| Renalytix Ai, INC. | $65.71 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Bayer Healthcare Pharmaceuticals INC. | $64.59 | 2022-2024 | |
| Corcept Therapeutics | $52.49 | 2024-2025 | Korlym |
| Merck Sharp & Dohme LLC | $48.10 | 2024 | Capvaxive, Gardasil, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $35.65 | 2022 | |
| Pfizer INC. | $29.59 | 2023-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.93 | 2022-2024 | Jardiance |
| Beta Bionics, INC. | $22.16 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lucid Diagnostics INC. | $21.82 | 2022 | |
| Abiomed | $20.50 | 2025 | |
| Lundbeck LLC | $18.79 | 2024 | Rexulti |
| Mylan Specialty L.P. | $17.33 | 2024 | Yupelri |
| Inspire Medical Systems, INC. | $16.81 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $16.63 | 2024 | Ajovy |
| Verona Pharma, INC. | $15.25 | 2025 | Ohtuvayre |
| Aimmune Therapeutics, INC. | $14.62 | 2025 | Zenpep |
| Antares Pharma, INC. | $13.69 | 2022 | |
| Cequr Corporation | $11.90 | 2024 | Cequr Simplicity |
| Phathom Pharmaceuticals, INC. | $9.19 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caitlin Lander listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.